Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about NovaBridge Biosciences
NovaBridge Biosciences News
Feb 19, 2026 - globenewswire.com
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
Feb 17, 2026 - globenewswire.com
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
NovaBridge Biosciences Quantitative Score
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NovaBridge Biosciences Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
NovaBridge Biosciences Financials
Table Compare
Compare NBP metrics with: | |||
|---|---|---|---|
Earnings & Growth | NBP | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NBP | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NBP | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NBP | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
NovaBridge Biosciences Income
NovaBridge Biosciences Balance Sheet
NovaBridge Biosciences Cash Flow
NovaBridge Biosciences Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
NovaBridge Biosciences Executives
| Name | Role |
|---|---|
| Claire Xu | Senior Vice President of Clinical Development |
| Phillip Dennis | Chief Medical Officer |
| Xi-Yong Fu | Chief Executive Officer & Director |
| Kyler Lei | Chief Financial Officer |
| Sean Wuxiong Cao | Chief Business Development Officer & Independent Director |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Claire Xu | Senior Vice President of Clinical Development | -- | ||
| Phillip Dennis | Chief Medical Officer | 1963 | -- | |
| Xi-Yong Fu | Chief Executive Officer & Director | 1972 | -- | |
| Kyler Lei | Chief Financial Officer | -- | ||
| Sean Wuxiong Cao | Chief Business Development Officer & Independent Director | Male | -- |